Abstract: An embodiment sliding transfer device for a vehicle includes a first rail part fixable to a vehicle body, a second rail part coupled to the first rail part and slidably movable in a forward-and-rearward direction of the first rail part, a plurality of sensors comprising a first sensor mounted at a front side of the first rail part and a second sensor mounted at a rear side of the first rail part, wherein each of the sensors is configured to generate a sensing signal in a case in which the second rail part reaches a set limit position thereof, and a controller configured to selectively control, based on the sensing signal, an operation of a drive motor for sliding movement of the second rail part.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: A battery module includes a structure so that gas or flame generated inside the battery module may be discharged stably. The battery module includes a cell assembly having at least one battery cell; a module case configured to accommodate the cell assembly in an inner space thereof and have a venting hole formed therein to discharge a venting gas generated from the cell assembly; and a venting unit provided at an outer side of the module case and configured to include an outer housing and an inner housing made of different materials, the venting unit being configured such that the venting gas discharged from the venting hole is introduced therein to flow along a surface of the inner housing and is discharged to the outside.

Abstract: Described is a sliding device allowing a user to switch between an electric sliding mode and a manual sliding mode as needed and including a guide rail module, a sliding rail slidably coupled to the guide rail module, a rail driving module coupled to the sliding rail and configured to move the sliding rail along the guide rail module by driving of a motor, and a sliding mode switching module configured to switch an operation mode of the sliding rail from an electric sliding mode to a manual sliding mode by blocking a driving force of the rail driving module from being transmitted to the sliding rail. The sliding device may be used for sliding a storage box for a vehicle.

Abstract: Provided are a separator and an electrochemical device using the same, in particular, a separator having significantly low heat shrinkage even at a high temperature and also significantly improved adhesive strength by including inorganic particles having specific fluorescence properties in the separator, and an electrochemical device using the same.

Abstract: A positive electrode active material for a secondary battery includes a lithium composite transition metal oxide comprising nickel (Ni), cobalt (Co), and manganese (Mn), and a coating layer formed on surfaces of the lithium composite transition metal oxide, wherein, in the lithium composite transition metal oxide, an amount of the nickel (Ni) in a total amount of transition metals is 60 mol % or more, and an amount of the manganese (Mn) is greater than an amount of the cobalt (Co), and the coating layer comprises a compound represented by Formula 1: LiaM1bOc ??[Formula 1] wherein, M1 includes aluminum (Al) and at least one selected from the group consisting of boron (B), silicon (Si), titanium (Ti), and phosphorus (P), and 1?a?4, 1?b?8, and 1?c?20.

Abstract: Provided is a method for preventing or improving UV-induced skin damage of a subject in need thereof, which comprises administering to the subject an effective amount of a composition containing hydrangenol derived from the extract of Hydrangea serrata as an active ingredient. The composition containing hydrangenol derived from the extract of Hydrangea serrata is able to increase secretion of hyaluronic acid and procollagen type-1 and inhibit secretion of MMP-1 in skin cells, and therefore effective in preventing or improving UV-induced damage of skin cells. Accordingly, the hydrangenol-containing composition is usefully available as a quasi-drug, drug, food, or cosmetic composition.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to a cosmetic composition for skin whitening comprising a small molecule-peptide conjugate. More specifically, it concerns the cosmetic composition for skin whitening comprising Caffeic acid-LG-NH2 or Coumaric acid-LG-NH2 as an active ingredient, which inhibits tyrosinase activity and melanin production, thereby showing an excellent skin whitening effect, and having no side effects to the skin by using a peptide component.

Abstract: The present invention relates to controlled and sustained release pharmaceutical composition and processes for preparing the same. The present invention is to provide processes to prepare an injectable sustained release pharmaceutical composition comprising a step to prepare biodegradable porous microspheres having accessible ionic functional groups, a step to incorporate a biopharmaceutical into the microspheres through ionic interaction by suspending or equilibrating the microspheres in a solution containing the biopharmaceutical and a step to recover and freeze-dry the biopharmaceutical-incorporated microspheres.

Abstract: Novel pyridyl imidazole derivatives of formula(I) inhibit effectively the action of angiotensin II and have a superior antihypertensive activity: ##STR1## wherein: A is a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl or alkenyl group, OR.sup.1 (wherein R.sup.1 is a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl or alkenyl radical), or NR.sup.2 R.sup.3 (wherein R.sup.2 and R.sup.3 are independently a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical);B is a group of the following formula ##STR2## D is a hydrogen; a halogen; a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl group which is optionally substituted with OH, a C.sub.1 -C.sub.4 alkoxy radical, CO.sub.2 R.sup.1, COR.sup.1, CON(R.sup.1).sub.2 or N(R.sup.1).sub.2, wherein R.sup.1 is the same as defined above; tetrazol-5-yl; a perfluoro-C.sub.1 -C.sub.4 alkyl group; or N(R.sup.1).sub.2, OR.sup.1, CO.sub.2 R.sup.1 or CON(R.sup.1).sub.2, wherein R.

Abstract: Novel imidazole derivatives of formula(I) inhibit effectively the action of angiotensin II and have a superior antihypertensive activity: ##STR1## wherein: A is a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl group, or OR.sub.1 wherein R.sub.1 is a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical; B is a halogen, CF.sub.3 or CF.sub.2 CF.sub.3 ; X is N or N-oxide; Y is --CH.sub.2 --, --CH(OR.sub.1)-- wherein R.sub.1 is the same as defined above, or --C(.dbd.O)--; n is 0 or an integer of 1 to 4; Z is a halogen, --OH, --OR.sub.1, --NR.sub.1 R.sub.2, --N(.dbd.O)R.sub.3 R.sub.4, --C(.dbd.O)R.sub.1, --C(.dbd.O)OR.sub.1, --CH(OR.sub.1).sub.2 or --C(.dbd.O)N.sub.1 N.sub.2 wherein R.sub.1 is the same as defined above, R.sub.2 is, independently of R.sub.1, a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical, and R.sub.3 and R.sub.4 are independently a straight, branched or cyclic C.sub.1 -C.sub.